statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Co. (NASDAQ:ABUS  Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.24 and traded as...

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average of $2.24

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Arbutus Biopharma management to meet virtually with JMP Securities

Investors considering a purchase of Arbutus Biopharma Corp (ABUS) stock, but cautious about paying the going market price of 2.56/share, might benefit from considering selling puts among the...

Commit To Buy Arbutus Biopharma At $2, Earn 19.3% Annualized Using Options

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Co. (NASDAQ:ABUS  Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 3,690,000...

Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 39.7% in February

Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M...

Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Barclays PLC lifted its stake in Arbutus Biopharma Co. (NASDAQ:ABUS  Free Report) by 175.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange...

Barclays PLC Boosts Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Volume	179,410.00
52-Wk High	$3.29
52-Wk Low	$1.69

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.11	--	--	N/A
Q4'23	-$0.12	-$0.12	-3.45%	MISSED
Q3'23	-$0.11	-$0.12	-7.14%	MISSED
Q2'23	-$0.11	-$0.10	10.71%	BEAT
Q1'23	-$0.14	-$0.10	26.47%	BEAT

ABUS Arbutus Biopharma Corp

About

Feed

News

Sentiment

Earnings

Fundamentals